Table 2 Linear regression analysis with log-transformed serum CGRP-LI levels (mol/l) T0
From: Serum CGRP in migraine patients using erenumab as preventive treatment
Variable | β (95% CI)1 | p | β (95% CI)2 | p |
|---|---|---|---|---|
Age | 0.07 (-0.001–0.13) | 0.05 | 0.07 (0.004–0.14) | 0.04 |
Sex | 1.92 (-0.41–4.25) | 0.10 | 2.50 (0.17–4.82) | 0.04 |
Migraine days baseline | 0.09 (-0.06–0.24) | 0.24 | 0.11 (-0.04–0.26) | 0.14 |
Serum CGRP-LI | -1.033 (-2.37–0.30) | 0.13 | -0.80 (-2.16–0.55) | 0.24 |
N = 94. 1Simple linear regression. 2multiple regression, corrected for all tested variables. CI = confidence interval. T0 = baseline, before starting treatment with erenumab. The outcome is absolute reduction migraine days during month 3 after starting treatment with erenumab compared to baseline. One month is defined as 28 days. | ||||